These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

447 related items for PubMed ID: 24898067

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines.
    La Monica S, Cretella D, Bonelli M, Fumarola C, Cavazzoni A, Digiacomo G, Flammini L, Barocelli E, Minari R, Naldi N, Petronini PG, Tiseo M, Alfieri R.
    J Exp Clin Cancer Res; 2017 Dec 04; 36(1):174. PubMed ID: 29202823
    [Abstract] [Full Text] [Related]

  • 3. T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.
    English DP, Bellone S, Schwab CL, Bortolomai I, Bonazzoli E, Cocco E, Buza N, Hui P, Lopez S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD.
    Cancer Med; 2014 Oct 04; 3(5):1256-65. PubMed ID: 24890382
    [Abstract] [Full Text] [Related]

  • 4. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
    Barok M, Tanner M, Köninki K, Isola J.
    Breast Cancer Res; 2011 Apr 21; 13(2):R46. PubMed ID: 21510863
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells.
    Wang H, Wang W, Xu Y, Yang Y, Chen X, Quan H, Lou L.
    Cancer Sci; 2017 Jul 21; 108(7):1458-1468. PubMed ID: 28388007
    [Abstract] [Full Text] [Related]

  • 8. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y, Yao K, Shi C, Jiang Y, Liu K, Zhao S, Chen H, Reddy K, Zhang C, Chang X, Ryu J, Bode AM, Dong Z, Dong Z.
    Oncotarget; 2015 Dec 29; 6(42):44274-88. PubMed ID: 26517520
    [Abstract] [Full Text] [Related]

  • 9. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    Schwarz LJ, Hutchinson KE, Rexer BN, Estrada MV, Gonzalez Ericsson PI, Sanders ME, Dugger TC, Formisano L, Guerrero-Zotano A, Red-Brewer M, Young CD, Lantto J, Pedersen MW, Kragh M, Horak ID, Arteaga CL.
    J Natl Cancer Inst; 2017 Nov 01; 109(11):. PubMed ID: 29059433
    [Abstract] [Full Text] [Related]

  • 10. Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations.
    Kayatani H, Ohashi K, Ninomiya K, Makimoto G, Nishii K, Higo H, Watanabe H, Kano H, Kato Y, Ninomiya T, Kubo T, Rai K, Ichihara E, Hotta K, Tabata M, Maeda Y, Kiura K.
    Biochem Biophys Res Commun; 2020 Nov 12; 532(3):341-346. PubMed ID: 32888648
    [Abstract] [Full Text] [Related]

  • 11. Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
    Cavazzoni A, Alfieri RR, Cretella D, Saccani F, Ampollini L, Galetti M, Quaini F, Graiani G, Madeddu D, Mozzoni P, Galvani E, La Monica S, Bonelli M, Fumarola C, Mutti A, Carbognani P, Tiseo M, Barocelli E, Petronini PG, Ardizzoni A.
    Mol Cancer; 2012 Dec 12; 11():91. PubMed ID: 23234355
    [Abstract] [Full Text] [Related]

  • 12. Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment.
    Askoxylakis V, Ferraro GB, Kodack DP, Badeaux M, Shankaraiah RC, Seano G, Kloepper J, Vardam T, Martin JD, Naxerova K, Bezwada D, Qi X, Selig MK, Brachtel E, Duda DG, Huang P, Fukumura D, Engelman JA, Jain RK.
    J Natl Cancer Inst; 2016 Feb 12; 108(2):. PubMed ID: 26547932
    [Abstract] [Full Text] [Related]

  • 13. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates.
    Erickson HK, Lewis Phillips GD, Leipold DD, Provenzano CA, Mai E, Johnson HA, Gunter B, Audette CA, Gupta M, Pinkas J, Tibbitts J.
    Mol Cancer Ther; 2012 May 12; 11(5):1133-42. PubMed ID: 22408268
    [Abstract] [Full Text] [Related]

  • 14. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
    Feng L, Yao HP, Zhou YQ, Zhou J, Zhang R, Wang MH.
    J Exp Clin Cancer Res; 2016 Apr 22; 35():70. PubMed ID: 27102688
    [Abstract] [Full Text] [Related]

  • 15. Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance.
    Dillon RL, Chooniedass S, Premsukh A, Adams GP, Entwistle J, MacDonald GC, Cizeau J.
    J Immunother; 2016 Apr 22; 39(3):117-26. PubMed ID: 26938945
    [Abstract] [Full Text] [Related]

  • 16. Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol.
    Ohashi K, Hotta K, Hirata T, Aoe K, Kozuki T, Ninomiya K, Kayatani H, Yanai H, Toyooka S, Hinotsu S, Takata M, Kiura K.
    Clin Lung Cancer; 2017 Jan 22; 18(1):92-95. PubMed ID: 27497829
    [Abstract] [Full Text] [Related]

  • 17. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
    Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, Tamura T, Nishio K, Nakagawa K, Tsurutani J.
    Int J Cancer; 2017 Oct 15; 141(8):1682-1689. PubMed ID: 28677116
    [Abstract] [Full Text] [Related]

  • 18. Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity.
    Ríos-Luci C, García-Alonso S, Díaz-Rodríguez E, Nadal-Serrano M, Arribas J, Ocaña A, Pandiella A.
    Cancer Res; 2017 Sep 01; 77(17):4639-4651. PubMed ID: 28687619
    [Abstract] [Full Text] [Related]

  • 19. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.
    Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX.
    Breast Cancer Res Treat; 2011 Jul 01; 128(2):347-56. PubMed ID: 20730488
    [Abstract] [Full Text] [Related]

  • 20. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
    Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T.
    Cancer Sci; 2016 Jul 01; 107(7):1039-46. PubMed ID: 27166974
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.